NFKB1 and chronic myelogenous leukemia, BCR-ABL1 positive: Since stachydrine at 40 and 80 μM is active against CML cells, our findings suggest that the inhibition of NF-κB signal pathway by stachydrine at 200 μM and above is not attributed to its anti-CML activity.